Headlines about XOMA Corporation (NASDAQ:XOMA) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. XOMA Corporation earned a news impact score of 0.08 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.8193424386617 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
XOMA Corporation (NASDAQ:XOMA) traded down 3.13% on Friday, reaching $22.59. 98,801 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $17.91 and a 200-day moving average price of $9.65. XOMA Corporation has a 1-year low of $3.96 and a 1-year high of $23.58. The company’s market capitalization is $171.64 million.
XOMA has been the subject of several recent research reports. Wedbush raised shares of XOMA Corporation from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $9.00 to $19.00 in a report on Tuesday, September 5th. Zacks Investment Research raised shares of XOMA Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. ValuEngine raised shares of XOMA Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of XOMA Corporation in a report on Thursday, August 10th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $14.00.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.